JP2020518613A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518613A5
JP2020518613A5 JP2019560156A JP2019560156A JP2020518613A5 JP 2020518613 A5 JP2020518613 A5 JP 2020518613A5 JP 2019560156 A JP2019560156 A JP 2019560156A JP 2019560156 A JP2019560156 A JP 2019560156A JP 2020518613 A5 JP2020518613 A5 JP 2020518613A5
Authority
JP
Japan
Prior art keywords
lamp
improved lamp
lamp construct
antigen
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518613A (ja
JP7222915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030725 external-priority patent/WO2018204534A1/en
Publication of JP2020518613A publication Critical patent/JP2020518613A/ja
Publication of JP2020518613A5 publication Critical patent/JP2020518613A5/ja
Priority to JP2022209238A priority Critical patent/JP7407902B2/ja
Application granted granted Critical
Publication of JP7222915B2 publication Critical patent/JP7222915B2/ja
Priority to JP2023213451A priority patent/JP7657282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560156A 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物 Active JP7222915B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209238A JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物
JP2023213451A JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762500053P 2017-05-02 2017-05-02
US62/500,053 2017-05-02
US201762561760P 2017-09-22 2017-09-22
US62/561,760 2017-09-22
PCT/US2018/030725 WO2018204534A1 (en) 2017-05-02 2018-05-02 Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209238A Division JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物

Publications (3)

Publication Number Publication Date
JP2020518613A JP2020518613A (ja) 2020-06-25
JP2020518613A5 true JP2020518613A5 (cg-RX-API-DMAC7.html) 2021-05-27
JP7222915B2 JP7222915B2 (ja) 2023-02-15

Family

ID=62528827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019560156A Active JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物
JP2022209238A Active JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209238A Active JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Country Status (10)

Country Link
US (2) US12358962B2 (cg-RX-API-DMAC7.html)
EP (1) EP3618854A1 (cg-RX-API-DMAC7.html)
JP (3) JP7222915B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240027895A (cg-RX-API-DMAC7.html)
CN (1) CN110913892A (cg-RX-API-DMAC7.html)
AU (1) AU2018263923B9 (cg-RX-API-DMAC7.html)
BR (1) BR112019023014A2 (cg-RX-API-DMAC7.html)
CA (1) CA3061950A1 (cg-RX-API-DMAC7.html)
IL (2) IL297073B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018204534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523185A (ja) * 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
GB9213033D0 (en) 1992-06-19 1992-08-05 British Telecomm Method of controlling a telecommunications network
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
JPH10501963A (ja) 1994-04-15 1998-02-24 ターゲテッド ジェネティクス コーポレイション 遺伝子送達融合タンパク質
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
WO1996000295A1 (en) 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL130198A (en) 1996-12-13 2005-09-25 Schering Corp Methods for purifying viruses
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
JP2002506436A (ja) 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ES2180258T3 (es) 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US20070269457A1 (en) 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
WO2011046996A2 (en) 2009-10-13 2011-04-21 The Johns Hopkins University Consensus sequence for influenza a virus
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
US20160185831A1 (en) 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
EP3157558A2 (en) 2014-06-23 2017-04-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs

Similar Documents

Publication Publication Date Title
US12162909B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
JP2023518596A5 (cg-RX-API-DMAC7.html)
ES2675825T3 (es) Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2
JP2017523789A5 (cg-RX-API-DMAC7.html)
JP6519929B2 (ja) Glp−1類似体融合タンパク質とその作製方法及び用途
JP2019506166A5 (cg-RX-API-DMAC7.html)
RU2016145061A (ru) Профилактическая вакцина против синдрома падения яйценоскости (eds)
JP2020532287A (ja) 癌の治療のためのネオアンチゲンワクチン組成物
WO2018232353A4 (en) Bacterial vaccine
US20160122420A1 (en) Antibody display
de Jesus Jimenez-Chavez et al. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer
JP2022525661A5 (cg-RX-API-DMAC7.html)
CN106279435A (zh) 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用
JP6373601B2 (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド
US20240189407A1 (en) Modified virus-like particles of bacteriophage ap205
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
KR20240176481A (ko) 융합 단백질 및 이의 용도
JP2025509352A5 (cg-RX-API-DMAC7.html)
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法
US11459364B2 (en) Calbindin and BH3 domain chimeric proteins and methods for use
Xu et al. Fusion of parathyroid hormone (1–34) to an albumin-binding domain improves osteogenesis
Drew et al. The human IgG3 hinge mediates the formation of antigen dimers that enhance humoral immune responses to DNA immunisation
US20230102159A1 (en) Malaria immunogen and methods for using same
US20260130979A1 (en) Malaria immunogen and methods of using same
US20240166696A1 (en) Scaffolds For Inducing Antibody Responses Against Antigenic Sites